Comparative economic evaluation of Haemophilus influenzae type b vaccination in Belarus and Uzbekistan.


Griffiths, UK; Clark, A; Shimanovich, V; Glinskaya, I; Tursunova, D; Kim, L; Mosina, L; Hajjeh, R; Edmond, K; (2011) Comparative economic evaluation of Haemophilus influenzae type b vaccination in Belarus and Uzbekistan. PLoS One, 6 (6). e21472. ISSN 1932-6203 DOI: 10.1371/journal.pone.0021472

[img]
Preview
Text - Published Version
License:

Download (339kB) | Preview

Abstract

BACKGROUND Hib vaccine has gradually been introduced into more and more countries during the past two decades, partly due to GAVI Alliance support to low-income countries. However, since Hib disease burden is difficult to establish in settings with limited diagnostic capacities and since the vaccine continues to be relatively expensive, some Governments remain doubtful about its value leading to concerns about financial sustainability. Similarly, several middle-income countries have not introduced the vaccine. The aim of this study is to estimate and compare the cost-effectiveness of Hib vaccination in a country relying on self-financing (Belarus) and a country eligible for GAVI Alliance support (Uzbekistan). METHODS AND FINDINGS A decision analytic model was used to estimate morbidity and mortality from Hib meningitis, Hib pneumonia and other types of Hib disease with and without the vaccine. Treatment costs were attached to each disease event. Data on disease incidence, case fatality ratios and costs were primarily determined from national sources. For the Belarus 2009 birth cohort, Hib vaccine is estimated to prevent 467 invasive disease cases, 4 cases of meningitis sequelae, and 3 deaths, while in Uzbekistan 3,069 invasive cases, 34 sequelae cases and 341 deaths are prevented. Estimated costs per discounted DALY averted are US$ 9,323 in Belarus and US$ 267 in Uzbekistan. CONCLUSION The primary reason why the cost-effectiveness values are more favourable in Uzbekistan than in Belarus is that relatively more deaths are averted in Uzbekistan due to higher baseline mortality burden. Two other explanations are that the vaccine price is lower in Uzbekistan and that Uzbekistan uses a three dose schedule compared to four doses in Belarus. However, when seen in the context of the relative ability to pay for public health, the vaccine can be considered cost-effective in both countries.

Item Type: Article
Faculty and Department: Faculty of Public Health and Policy > Dept of Health Services Research and Policy
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Faculty of Public Health and Policy > Dept of Global Health and Development
Research Centre: Vaccine Centre
Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 21720546
Web of Science ID: 292036900035
URI: http://researchonline.lshtm.ac.uk/id/eprint/429

Statistics


Download activity - last 12 months
Downloads since deposit
210Downloads
323Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item